Kane Biotech Inc.
KNBIF
$0.0643
-$0.002-3.02%
| 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | |
|---|---|---|---|---|---|
| Revenue | 4,579.10% | 2,008.84% | 47.51% | 102.97% | -95.41% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 4,579.10% | 2,008.84% | 47.51% | 102.97% | -95.41% |
| Cost of Revenue | 20,315.38% | 4,650.00% | 66.04% | 102.65% | -98.88% |
| Gross Profit | 2,241.14% | 1,405.71% | 42.79% | 103.25% | -91.53% |
| SG&A Expenses | 35.39% | 339.52% | 30.56% | 234.76% | -31.70% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 86.58% | 504.61% | 36.39% | 193.33% | -31.79% |
| Operating Income | 38.11% | -331.48% | -35.95% | -128.39% | -10.90% |
| Income Before Tax | 46.35% | -75.08% | -34.53% | -61.22% | -16.46% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 46.35% | -75.08% | -34.53% | -61.22% | -16.46% |
| Earnings from Discontinued Operations | 153.35% | 5,455.32% | 212.89% | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 56.78% | 1,133.19% | -16.59% | -104.41% | -32.57% |
| EBIT | 38.11% | -331.48% | -35.95% | -128.39% | -10.90% |
| EBITDA | 39.04% | -438.13% | -43.16% | -121.06% | -12.59% |
| EPS Basic | 59.26% | 1,075.00% | -11.27% | -115.00% | -26.56% |
| Normalized Basic EPS | 50.00% | -68.00% | -29.27% | -79.31% | -17.95% |
| EPS Diluted | 15.85% | 585.71% | -11.27% | 117.50% | -28.13% |
| Normalized Diluted EPS | 50.00% | -59.09% | -29.27% | -79.31% | -17.95% |
| Average Basic Shares Outstanding | 5.51% | 5.94% | 5.62% | 5.32% | 4.16% |
| Average Diluted Shares Outstanding | 5.51% | 8.21% | 5.62% | 5.32% | 4.16% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
